Literature DB >> 1536715

Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography.

P Hartvig1, K J Lindner, J Tedroff, P Bjurling, K Hörnfelt, B Långström.   

Abstract

The regional brain kinetics of (beta-11C)-L-dopa and 6-fluoro-(beta-11C)-L-dopa was measured in six Rhesus monkeys using positron emission tomography (PET). Radioactivity accumulated specifically in the striatal region and the increase in L-dopa-derived radioactivity utilization with time was calculated using surrounding brain as a reference area, this being devoid of dopaminergic activity. The rate constant for selective striatal utilization i.e. grossly decarboxylation was 0.0110 +/- 0.0007 (S.D) and 0.0057 +/- 0.0006 min-1 for (beta-11C)-L-dopa and 6-fluoro-(beta-11C)-L-dopa, respectively. After pretreatment of the monkeys with the peripherally and centrally active catecholamine-O-methyl transferase (COMT) inhibitor Ro 40-7592 10 mg/kg, the decarboxylation rate remained unchanged (0.0112 +/- 0.0015 min-1) for (beta-11C)-L-dopa, whereas an increase in rate was measured for 6-fluoro-(beta-11C)-L-dopa (0.0092 +/- 0.0015 min-1). Differences in the distribution of radiolabelled metabolites i.e. the corresponding O-methyl-L-dopa in the reference area is most probably the reason for the difference in calculated decarboxylation rate seen between the radiotracers. The higher decarboxylation rate measured for 6-fluoro-(beta-11C)-L-dopa after blockade of COMT shows that the radiolabelled metabolites i.e. 6-fluoro-O-methyl-(beta-11C)-L-dopa significantly contributes to background radioactivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536715     DOI: 10.1007/bf01253107

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  20 in total

1.  IN-VITRO DECARBOXYLATION OF NEW PHENYLALANINE DERIVATIVES.

Authors:  R FERRINI; A GLAESSER
Journal:  Biochem Pharmacol       Date:  1964-05       Impact factor: 5.858

2.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

3.  Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.

Authors:  J Tedroff; S M Aquilonius; P Hartvig; H Lundqvist; P Bjurling; B Långström
Journal:  Acta Neurol Scand       Date:  1992-03       Impact factor: 3.209

4.  Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate.

Authors:  G Firnau; S Sood; R Chirakal; C Nahmias; E S Garnett
Journal:  J Neurochem       Date:  1987-04       Impact factor: 5.372

5.  The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study.

Authors:  M K Horne; C H Cheng; G F Wooten
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

6.  Dopamine visualized in the basal ganglia of living man.

Authors:  E S Garnett; G Firnau; C Nahmias
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

7.  Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

Authors:  E S Garnett; C Nahmias; G Firnau
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

8.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease.

Authors:  D B Calne; J W Langston; W R Martin; A J Stoessl; T J Ruth; M J Adam; B D Pate; M Schulzer
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

9.  Central action of benserazide after COMT inhibition demonstrated in vivo by PET.

Authors:  J Tedroff; P Hartvig; P Bjurling; Y Andersson; G Antoni; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991

10.  Metabolites of 6-[18F]fluoro-L-dopa in human blood.

Authors:  G Firnau; S Sood; R Chirakal; C Nahmias; E S Garnett
Journal:  J Nucl Med       Date:  1988-03       Impact factor: 10.057

View more
  5 in total

1.  Brain kinetics of 11 C-labelled L-tryptophan and 5-hydroxy-L-tryptophan in the rhesus monkey. A study using positron emission tomography.

Authors:  P Hartvig; K J Lindner; J Tedroff; Y Andersson; P Bjurling; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  Exploring Metabolism In Vivo Using Endogenous 11C Metabolic Tracers.

Authors:  Kiel Neumann; Robert Flavell; David M Wilson
Journal:  Semin Nucl Med       Date:  2017-07-11       Impact factor: 4.446

Review 3.  From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application.

Authors:  Aleksandra Pekošak; Ulrike Filp; Alex J Poot; Albert D Windhorst
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

4.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

5.  Central action of benserazide after COMT inhibition demonstrated in vivo by PET.

Authors:  J Tedroff; P Hartvig; P Bjurling; Y Andersson; G Antoni; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.